Market Research Logo

Insulin Pens - Medical Devices Pipeline Assessment, 2016

Insulin Pens - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Insulin Pens - Medical Devices Pipeline Assessment, 2016 provides an overview of Insulin Pens currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Insulin Pens pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Insulin Pens under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Insulin Pens and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Insulin Pens under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Insulin Pens Overview
3 Products under Development
3.1 Insulin Pens - Pipeline Products by Stage of Development
3.2 Insulin Pens - Pipeline Products by Segment
3.3 Insulin Pens - Pipeline Products by Territory
3.4 Insulin Pens - Pipeline Products by Regulatory Path
3.5 Insulin Pens - Pipeline Products by Estimated Approval Date
4 Insulin Pens - Pipeline Products under Development by Companies
4.1 Insulin Pens Companies - Pipeline Products by Stage of Development
4.2 Insulin Pens - Pipeline Products by Stage of Development
5 Insulin Pens Companies and Product Overview
5.1 Becton, Dickinson and Company Company Overview
5.1.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview
5.2 Calibra Medical, Inc. Company Overview
5.2.1 Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.3 Cambridge Consultants Limited Company Overview
5.3.1 Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview
5.4 Companion Medical, Inc. Company Overview
5.4.1 Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.5 Emperra GmbH E-Health Technologies Company Overview
5.5.1 Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview
5.6 MedPro Safety Products, Inc. Company Overview
5.6.1 MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.7 MicroPort Scientific Corporation Company Overview
5.7.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.8 Sanofi Company Overview
5.8.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview
6 Insulin Pens- Recent Developments
6.1 Mar 23, 2016: B. Braun's growth trend continues
6.2 Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer
6.3 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
6.4 Mar 07, 2016: InsuLine Medical to Raise Funds in Financing Round
6.5 Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance
6.6 Feb 04, 2016: Sanofi India Announces Results for the Quarter & Year Ended December 31, 2015
6.7 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter
6.8 Jan 26, 2016: Antares Pharma Announces CEO Transition
6.9 Jan 21, 2016: U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen
6.10 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges
6.11 Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%
6.12 Jan 11, 2016: Insulet Enters into Co-Development Agreement with Eli Lilly
6.13 Jan 05, 2016: Ypsomed Enters into Distribution Agreement with Tonghua Dongbao Pharma
6.14 Dec 04, 2015: Change in B. Braun Management Board
6.15 Dec 01, 2015: Owen Mumford Launches New Touch Activated Lancet
6.16 Nov 20, 2015: Sanofi India Announces Sale of Building in Andheri, Mumbai
6.17 Nov 05, 2015: Antares Pharma Reports Third Quarter 2015 Operating and Financial Results
6.18 Nov 04, 2015: BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance
6.19 Oct 20, 2015: Sanofi India - Outcome of Board Meeting
6.20 Oct 20, 2015: Sanofi India Announces Q3 results & Limited Review Report for the quarter ended September 30, 2015
6.21 Sep 22, 2015: Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran
6.22 Sep 16, 2015: Sanofi's CSR Achievements Recognized In The Dow Jones Sustainability Indices
6.23 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility & Introduces Basalog One
6.24 Sep 15, 2015: Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million
6.25 Sep 15, 2015: Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million
6.26 Sep 15, 2015: BD Named 2015 Outstanding Corporate Innovator Winner by Product Development and Management Association
6.27 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility
6.28 Aug 24, 2015: Biocon Clarifies On FDA’s Inspection
6.29 Aug 18, 2015: Lilly's Humalog 200 units/mL KwikPen Now Available in U.S. Pharmacies
6.30 Aug 10, 2015: Antares Pharma Reports Second Quarter 2015 Operating and Financial Results
6.31 Aug 06, 2015: BD Announces Results for 2015 Third Fiscal Quarter and Raises EPS Guidance for Fiscal 2015
6.32 Jul 30, 2015: Sanofi delivers solid sales and business EPS(1) growth in Q2 2015
6.33 Jul 23, 2015: Biocon's Earnings Surge in Q1 FY16; Revenue up by 15% at Rs. 857 Crore, Net Profit up by 23% at Rs. 126 Crore
6.34 Jul 23, 2015: Appointment of Chief Financial Officer : Sanofi India
6.35 Jul 21, 2015: Sanofi India Announces Q2 results
6.36 Jul 15, 2015: Sanofi Announces New, Global Business Unit Structure To Drive Future Growth
6.37 Jul 15, 2015: BD Opens Advance Diabetes Care Headquarters in Andover, Mass.
6.38 Jul 14, 2015: Antares Pharma Appoints Peter J. Graham Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary
6.39 Jul 13, 2015: BD Announces Sustainability Goals for 2020
6.40 Jul 09, 2015: Gerresheimer substantially improves operating earnings in second quarter
6.41 Jul 08, 2015: BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts
6.42 Jul 01, 2015: Haselmeier Group Announces the Extension and Reorganization of its Executive Board
6.43 Jun 30, 2015: Ypsomed now supplies the YpsoPen in Poland
6.44 Jun 24, 2015: EMPERRA's Bluetooth-enabled ESYSTA Smart Insulin Pen in the Last Stages of the CE Approval Process
6.45 Jun 06, 2015: New Clinical Data Suggest Infusion Set with BD FlowSmart Technology May Improve Insulin Flow and Reduce Silent Occlusions
6.46 Jun 02, 2015: BD Participates in White House Forum on Antibiotic Stewardship
6.47 May 27, 2015: U.S. Food and Drug Administration Approves Humalog 200 units/mL KwikPen
6.48 May 21, 2015: Haselmeier receives prestigious accolade for two of their products: The international GOOD DESIGN Award 2014
6.49 May 20, 2015: Companion Medical Raises USD3.15 Million in Series B Financing
6.50 May 18, 2015: Haselmeier Group Announces the Relocation of Haselmeier in the United States
6.51 May 15, 2015: Sanofi Announces Departure Of Chief Strategy Officer
6.52 May 13, 2015: DuBiotech Welcomes Germany’s B.Braun
6.53 May 11, 2015: Antares Pharma Reports First Quarter 2015 Operating and Financial Results
6.54 May 11, 2015: Antares Pharma Reports First Quarter 2015 Financial and Operating Results
6.55 May 07, 2015: BD Announces Results For 2015 Second Fiscal Quarter
6.56 May 07, 2015: Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Insulin Pens - Pipeline Products by Stage of Development
Table 2: Insulin Pens - Pipeline Products by Segment
Table 3: Insulin Pens - Pipeline Products by Territory
Table 4: Insulin Pens - Pipeline Products by Regulatory Path
Table 5: Insulin Pens - Pipeline Products by Estimated Approval Date
Table 6: Insulin Pens Companies - Pipeline Products by Stage of Development
Table 7: Insulin Pens - Pipeline Products by Stage of Development
Table 8: Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Next Generation Pen Needle II - Product Status
Table 10: Next Generation Pen Needle II - Product Description
Table 11: Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Pre-Filled Insulin Device - Product Status
Table 13: Pre-Filled Insulin Device - Product Description
Table 14: Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 15: KiCoPen - Product Status
Table 16: KiCoPen - Product Description
Table 17: Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Insulin Pen - Product Status
Table 19: Insulin Pen - Product Description
Table 20: Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Status
Table 22: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Description
Table 23: MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Insulin Guard Self-Injector Safety Needle - Product Status
Table 25: Insulin Guard Self-Injector Safety Needle - Product Description
Table 26: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 27: La Fenice Pen - Product Status
Table 28: La Fenice Pen - Product Description
Table 29: Sanofi Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Fix-Flex Device - Product Status
Table 31: Fix-Flex Device - Product Description
Table 32: Glossary
1.2 List of Figures
Figure 1: Insulin Pens - Pipeline Products by Stage of Development
Figure 2: Insulin Pens - Pipeline Products by Segment
Figure 3: Insulin Pens - Pipeline Products by Territory
Figure 4: Insulin Pens - Pipeline Products by Regulatory Path
Figure 5: Insulin Pens - Pipeline Products by Estimated Approval Date

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report